๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ulcerative Colitis (UC)
Clinical trial register · China

Ulcerative Colitis (UC) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 9 Shanghai 6 Wuhan 3 Hefei 3 Beijing 3
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou9 Shanghai6 Wuhan3 Hefei3 Beijing3
All 30 locations
Target enrolment
to

Ulcerative Colitis (UC) trials in China

22 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Alpha-0261 Tablets for Moderate-to-Severe Ulcerative Colitis
NCT07744646Ulcerative Colitis (UC)
The First Affiliated Hospital of Anhui Medical University
Phase 1
10
Hefei
2026-08-03
Not yet open
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PTT-621 in Patients With Moderately to Severely Active Ulcerative Colitis
NCT07747155Ulcerative Colitis (UC)
Pyrotech Therapeutics, Inc.
Phase 2
40
Shanghai
2026-08
Not yet open
A National Multicenter Study of Etrasimod for the Treatment of Patients With Active UC
NCT07705126Ulcerative Colitis (UC)
Tang-Du Hospital
Observational
500
Xiโ€™an
2026-07-15
By invitation
Predictive Efficacy of Fecal Calprotectin Assay by Magnetic Particle Chemiluminescence for Mucosal Healing in Moderate-to-Severe Ulcerative Colitis Patients Undergoing Initial Biologic Therapy๏ผˆPRECAL๏ผ‰
NCT07721441Ulcerative Colitis (UC)
Tang-Du Hospital
Observational
200
Beijing, Chongqing, Shenzhen, Wuhan, Nanjing, Shengyang, Qingdao, Xiโ€™an
2026-06-18
Recruiting
A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis
NCT07692165Ulcerative Colitis (UC)
Innatus Therapeutics (Shanghai) Co., Ltd.
Phase 1/2
24
Guangzhou, Shenyang, Beijing, Hangzhou, Shanghai, Taiyuan, Weifang, Wenzhou
2026-06-11
Not yet open
Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis
NCT07650942Ulcerative Colitis (UC)
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
360
Guangzhou
2026-06
Recruiting
A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult
NCT07632573Ulcerative Colitis (UC), Ulcerative Colitis (Disorder), Ulcerative Colitis Acute, IBD (Inflammatory Bowel Disease)
Benethera (Shaoxing) Biotechnology Co., Ltd.
Phase 1
68
Hangzhou
2026-05-18
Recruiting
The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC
NCT07507513Ulcerative Colitis (UC)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
288
Guangzhou
2026-03-28
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Eli Lilly and Company
Phase 2
1,431
Binzhou, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Harbin, Hefei
2026-03-26
Recruiting
Fecal Microbiota Transplantation for Ulcerative Colitis Using Dai and Han Donors
NCT07814456Ulcerative Colitis (UC), Inflammatory Bowel Disease
First Affiliated Hospital of Kunming Medical University
Phase 2
200
Kunming
2026-02-03
Recruiting
A Study for HSK47388 in Participants With Ulcerative Colitis
NCT07335055Ulcerative Colitis (UC)
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
150
Hangzhou
2026-02-03
Not yet open
A Study of Cizutamig for Patients With Ulcerative Colitis
NCT07353450Ulcerative Colitis (UC)
Ruijin Hospital
Phase EARLY_PHASE1
15
Shanghai
2026-01
Recruiting
Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics
NCT07261826Clostridium Difficile Infection Recurrence, Ulcerative Colitis (UC), Crohn Disease (CD), Irritable Bowel Syndrome (IBS)
Chen QiYi
Observational
4,000
Shanghai
2025-09-01
Recruiting
Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis
NCT07111572Ulcerative Colitis (UC), Fecal Calprotetin, FIT
Qilu Hospital of Shandong University
Observational
100
Jinan
2025-08-01
Recruiting
DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis
NCT07111273Ulcerative Colitis (UC), Fecal Calprotetin, FIT, Biomarker
Qilu Hospital of Shandong University
Observational
100
Jinan
2025-08-01
Not yet open
hucMSCs Exosomes for the Treatment of Active Ulcerative Colitis
NCT06853522Ulcerative Colitis (UC)
Shanghai East Hospital
Phase EARLY_PHASE1
40
Shanghai
2025-05-30
Recruiting
Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis
NCT06962020Ulcerative Colitis (UC)
Xijing Hospital of Digestive Diseases
Observational
400
Shanxi
2025-04-30
Recruiting
Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
NCT06095596Ulcerative Colitis (UC)
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
334
Guangzhou
2023-11-01
Recruiting
Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis
NCT07442045Ulcerative Colitis (UC)
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
150
Foshan, Guangzhou, Shenzhen
2023-01-01
Recruiting
IBD Biomarker Discovery and Validation Platform
NCT07686406Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Diseases (IBD)
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
6,000
Guangzhou
2022-01-01
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
AbbVie
Phase 3
1,242
Hefei, Beijing, Guangzhou, Shijiazhuang, Wuhan, Changsha, Huaian, Nanjing
2018-08-28
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068Ulcerative Colitis (UC)
AbbVie
Phase 3
950
Guangzhou, Shiyan, Wuhan, Changsha, Nanchang, Changchun, Shenyang, Shanghai
2017-01-31
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/ulcerative-colitis-uc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies listing the condition Ulcerative Colitis (UC).

How many Ulcerative Colitis (UC) trials are recruiting in China?

13 of the 22 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 2 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ulcerative Colitis (UC)), 22 studies
PhaseStudiesRecruitingShare
Observational8636.4%
Phase 25422.7%
Phase 33013.6%
Phase 1219.1%
Phase EARLY_PHASE1209.1%
Not applicable114.5%
Phase 1/2114.5%

Most active sponsors

Lead sponsors with the most studies (Ulcerative Colitis (UC))
Lead sponsorStudiesRecruiting
Sixth Affiliated Hospital, Sun Yat-sen University33
AbbVie20
Qilu Hospital of Shandong University22
Tang-Du Hospital20
Benethera (Shaoxing) Biotechnology Co., Ltd.11
Chen QiYi11
Eli Lilly and Company11
First Affiliated Hospital of Kunming Medical University11
Ganzhou Hemay Pharmaceutical Co., Ltd10
Haisco Pharmaceutical Group Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.